We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
InteRNA Technologies, UCB and University of Bonn to Collaborate
News

InteRNA Technologies, UCB and University of Bonn to Collaborate

InteRNA Technologies, UCB and University of Bonn to Collaborate
News

InteRNA Technologies, UCB and University of Bonn to Collaborate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "InteRNA Technologies, UCB and University of Bonn to Collaborate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

InteRNA Technologies B.V. and the Neuroallianz Consortium, an academic industry partnership with UCB and the Rheinische Friedrich-Wilhelms-University of Bonn (Germany) as 2 of the total 10 partners have entered into an agreement where InteRNA will support the investigation of miRNAs in neurodegenerative diseases.

Under the agreement, InteRNA, working closely with Jeroen Pasterkamp, Professor of Translational Neuroscience at UMC Utrecht, will apply its platform for multi-parametric, high-throughput functional screening assays to identify and validate the biological role of individual miRNAs and novel therapeutic targets for neurodegenerative disease.

This collaboration forms an integral part of the Neuroallianz project miRNAs in Neurodegenerative Diseases partnered by the University of Bonn and UCB and funded by the Federal Ministry for Education and Research (BMBF) in Germany.

Though InteRNA is building its own pipeline of miRNA drug candidates for cancer, it has shown validity of its platform for discovery and validation of miRNAs drug candidates and their mode of action for other disease indications.

“The selection of InteRNA to support this program validates the uniqueness of our platform and confirms its potential use outside oncology”, said Roel Schaapveld, CEO of InteRNA Technologies.

Advertisement